Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
Search insider filingsAll Congress filings
MORE TOOLS
WatchlistGold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeSearch insider filingsAll Congress filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…Scanning SEC filings…Checking Congress reports…Following the signal…

HomeSearchCongressWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View VRDN insider activity ↗

VRDNViridian Therapeutics, Inc.\DE

THE LATEST REPORTED YEAR

The company reported a loss.

$342.6M net loss for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.

Revenue$70.85MYear ended December 31, 2025
Profit or loss-$342.6MYear ended December 31, 2025
Cash from the business-$276.39MYear ended December 31, 2025
Total assets$1.1BAs of June 30, 2026
Total liabilities$435.14MAs of June 30, 2026
Cash & equivalents$24.86MAs of September 30, 2019
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$8.39M
2018-12
$4.46M
2019-12
$1.05M
2020-12
$2.96M
2021-12
$1.77M
2022-12
$314K
2023-12
$302K
2024-12
$70.85M
2025-12

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
January 1, 2025 – December 31, 2025$70,849,000February 26, 202610-K ↗
January 1, 2024 – December 31, 2024$302,000February 26, 202610-K ↗
January 1, 2023 – December 31, 2023$314,000February 26, 202610-K ↗
January 1, 2022 – December 31, 2022$1,772,000March 3, 202510-K ↗
January 1, 2021 – December 31, 2021$2,963,000February 27, 202410-K ↗
January 1, 2020 – December 31, 2020$1,050,000March 11, 202210-K ↗
January 1, 2019 – December 31, 2019$4,461,000March 26, 202110-K ↗
January 1, 2018 – December 31, 2018$8,386,000March 13, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · Retrieved October 11, 2026

Response SHA-256: 907b594c863d597442ab1ef3a5d74359a9418f23c7e0bb102180e38d47e78bab

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.